Evidence map›Paper›PMID 33675748›Full record

ArticleThe Journal of biological chemistry

A long isoform of GIV/Girdin contains a PDZ-binding module that regulates localization and G-protein binding.

Jason Ear, Amer Ali Abd El-Hafeez, Suchismita Roy, Tony Ngo, Navin Rajapakse, Julie Choi, Soni Khandelwal, Majid Ghassemian, Luke McCaffrey, Irina Kufareva and 2 more

Open access · goldAbstract read
In one paragraph

Article in The Journal of biological chemistry. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Jason EarDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California, USA; Biological Sciences Department, California State Polytechnic University, Pomona, California, USA. Electronic address: jear@cpp.edu.
Amer Ali Abd El-HafeezDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California, USA; Pharmacology and Experimental Oncology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Suchismita RoySkaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, USA.
Tony NgoSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, USA.
Navin RajapakseDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California, USA.
Julie ChoiDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California, USA.
Soni KhandelwalDepartment of Pediatrics, University of California San Diego, La Jolla, California, USA.
Majid GhassemianDepartment of Chemistry and Biochemistry, University of California San Diego, La Jolla, California, USA.
Luke McCaffreyRosalind and Morris Goodman Cancer Research Centre, McGill University, Montreal, Canada; Gerald Bronfman Department of Oncology, McGill University, Montreal, Canada.
Irina KufarevaSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, USA.
Debashis SahooDepartment of Pediatrics, University of California San Diego, La Jolla, California, USA.
Pradipta GhoshDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California, USA; Department of Medicine, University of California San Diego, La Jolla, California, USA; Rebecca and John Moore Comprehensive Cancer Center, University of California San Diego, La Jolla, California, USA; Veterans Affairs Medical Center, La Jolla, California, USA. Electronic address: prghosh@ucsd.edu.
University of California San Diego · USCairo University · EGMcGill University Health Centre · CAVeterans Health Administration · US

Funding

UCSD Cancer Center Training Program in Drug DevelopmentT32CA121938 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Bouvet, Dwayne G. Stupack · 2006 to 2026
$10.3M
Spatial Regulation of RGS and G Protein SignalingR01CA100768 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GHOSH, PRADIPTA · 2003 to 2019
$7.4M
Predoctoral and Postdoctoral Training in Cancer Cell BiologyT32CA067754 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JEAN Y.J. WANG · 1995 to 2026
$6.5M
Macrophage Polarization in Response to Infections and InflammationR01AI155696 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GHOSH, PRADIPTA, SAHOO, DEBASHIS · 2020 to 2024
$4.9M
Modulation of Macrophage Polarization by Heterotrimeric G proteins: Implications of Gastrointestinal InflammationR01AI141630 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Pradipta Ghosh · 2019 to 2026
$3.2M
Integrators of Metastatic PotentialR01CA238042 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GHOSH, PRADIPTA, LUKER, GARY D · 2019 to 2023
$2.3M
Innate responses following infection with enteric microbesR01DK107585 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DAS, SOUMITA · 2016 to 2020
$2.2M
Summer Student Research on the Application of Boolean AnalysisR01GM138385 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SAHOO, DEBASHIS · 2020 to 2023
$2.0M
Modulation of G proteins by Growth FactorsR01CA160911 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GHOSH, PRADIPTA · 2013 to 2017
$1.8M
Network-Based Novel Therapeutics in Colorectal CancersUG3TR002968 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DAS, SOUMITA, GHOSH, PRADIPTA · 2019 to 2021
$946k
Precision therapeutics of inflammatory bowel disease guided by Boolean logicUG3TR003355 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DAS, SOUMITA, GHOSH, PRADIPTA · 2020 to 2022
$937k
Application of Boolean Networks to discover stem and progenitor cellsR00CA151673 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SAHOO, DEBASHIS · 2014 to 2016
$717k
NCATS NIH HHS UG3 TR002968NCATS NIH HHS UG3 TR003355NCI NIH HHS R00 CA151673NCI NIH HHS R01 CA100768NCI NIH HHS R01 CA160911NCI NIH HHS R01 CA238042NCI NIH HHS T32 CA067754NCI NIH HHS T32 CA121938NIAID NIH HHS R01 AI141630NIAID NIH HHS R01 AI155696NIAID NIH HHS R21 AI156662NIDDK NIH HHS R01 DK107585NIGMS NIH HHS R01 GM138385
6 · The paper itself

Abstract

PDZ domains are one of the most abundant protein domains in eukaryotes and are frequently found on junction-localized scaffold proteins. Various signaling molecules bind to PDZ proteins via PDZ-binding motifs (PBM) and fine-tune cellular signaling. However, how such interaction affects protein function is difficult to predict and must be solved empirically. Here we describe a long isoform of the guanine nucleotide exchange factor GIV/Girdin (CCDC88A) that we named GIV-L, which is conserved throughout evolution, from invertebrates to vertebrates, and contains a PBM. Unlike GIV, which lacks PBM and is cytosolic, GIV-L localizes onto cell junctions and has a PDZ interactome (as shown through annotating Human Cell Map and BioID-proximity labeling studies), which impacts GIV-L's ability to bind and activate trimeric G-protein, Gαi, through its guanine-nucleotide exchange modulator (GEM) module. This GEM module is found exclusively in vertebrates. We propose that the two functional modules in GIV may have evolved sequentially: the ability to bind PDZ proteins via the PBM evolved earlier in invertebrates, whereas G-protein binding and activation may have evolved later only among vertebrates. Phenotypic studies in Caco-2 cells revealed that GIV and GIV-L may have antagonistic effects on cell growth, proliferation (cell cycle), and survival. Immunohistochemical analysis in human colon tissues showed that GIV expression increases with a concomitant decrease in GIV-L during cancer initiation. Taken together, these findings reveal how regulation in GIV/CCDC88A transcript helps to achieve protein modularity, which allows the protein to play opposing roles either as a tumor suppressor (GIV-L) or as an oncogene (GIV).

Indexed as

AnimalsCell LineCell Line, TumorCell ProliferationColonic NeoplasmsGTP-Binding Protein alpha Subunits, Gi-GoGuanine Nucleotide Exchange FactorsHumansMicrofilament ProteinsPDZ DomainsPhosphorylationProtein BindingProtein IsoformsProtein TransportSignal TransductionVesicular Transport ProteinsCCDC88A protein, humanGTP-Binding Protein alpha Subunits, Gi-GoGuanine Nucleotide Exchange FactorsMicrofilament ProteinsProtein IsoformsVesicular Transport Proteinscancercell biologycell junctionscell signalingprotein interactions

Identifiers

PMID33675748
PMCPMC8042451
OpenAlexW3134382340

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.